The UK and US have hammered out a important commercial pact that will ensure zero levies on British drug products entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This commitment ensures that duties on these crucial exports will remain at zero for a timeframe of three years.
This agreement comes after recent warnings to dramatically increase duties on branded drug products, with increases discussed as high as double the cost.
"This arrangement with the UK strengthens the worldwide climate for innovative medicines and brings much-needed equity to U.S.–U.K. medicine commerce," a statement declared.
Trade Importance
Drugs are one of the UK's largest export categories to the America, which is clearly the largest buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This amount represented a significant portion of total UK exports in that span.
"This deal secures employment, increases funding and sets the stage for the UK to emerge as a international leader for life sciences," a government official commented.
Key British Pledges
The pact includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to raise total health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds were more than 20%.
Broader Context
The deal comes amid a protracted tension between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
These tensions were intensified by arguments that American patients were paying a premium for the identical medicines than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the last ten years.
